Document text
Maternal/Pediatric Respiratory Syncytial Virus (RSV)
Work Group
Sarah S. Long, MD
Chair, Maternal/Pediatric RSV Work Group
ACIP Meeting
June 28, 2024National Center for Immunization and Respiratory Diseases
•RSV prevention in infants during their first RSV season (i.e., aged <8 months)
-To protect infants in their first season , either maternal RSV vaccination ( Abrysvo ,
Pfizer), or use of nirsevimab (Beyfortus , Sanofi and AstraZeneca) in the infant is
recommended to prevent RSV lower respiratory tract disease
-Administration of both products is not needed for most infants
•Children ages 8 –19 months who are at increased risk of severe RSV disease and
entering their second RSV season are recommended to receive one dose of
nirsevimabTwo products are recommended to protect infants and
young children from RSV lower respiratory tract disease
https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm
https://www.cdc.gov/mmwr/volumes/72/wr/mm7241e1.htm 2
Timing of RSV vaccine and nirsevimab
Figure represents recommended timing of immunization product deployment for most of the continental U.S. In jurisdictions with
seasonality that differs from most of the continental United States (e.g., Alaska, jurisdictions with tropical climates), pro viders should
follow state, local, or territorial guidance on timing of administration
Mother can get RSV vaccine
(Abrysvo) during pregnancy
Infant can get RSV antibody
(nirsevimab) after birth
•Maternal RSV vaccine
-For pregnant people at 32 –36 weeks’ gestation, vaccinate using seasonal administration
(meaning September –January in most of the United States)
•Nirsevimab1
-For infants <8 months of age, immunize shortly before season onset (e.g., October)
-Forinfants born during October –March , immunize within 1 week of birthTiming of administration of maternal Pfizer RSV vaccine (Abrysvo)
and nirsevimab (Beyfortus)
https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm; https://www.cdc.gov/mmwr/volumes/72/wr/mm7241e1.htm
1In jurisdictions with seasonality that differs from most of the continental United States (e.g., Alaska, jurisdictions with t ropical climates), providers should follow state, local, or
territorial guidance on timing of administration
3
•Multiple products introduced in the same season
created confusion among healthcare workers as to
which groups were eligible for which immunizations
•Rare reports of administration errors were received
by the Vaccine Adverse Events Reporting System
(VAERS)
-Reports of pregnant persons receiving Arexvy
(GSK’s vaccine for older adults)
-Reports of children receiving RSV vaccine instead
of monoclonal antibody products (e.g.,
nirsevimab )
-Wrong dose ( nirsevimab ) administered
•CDC made additional resources available and
increased education efforts with healthcare
providersVaccine administration errors reported in young
children and pregnant people
Information on Respiratory Syncytial Virus (RSV) Vaccine Administration
Errors in Young Children and Pregnant People
Administration of the GSK Respiratory Syncytial Virus Vaccine to Pregnant
Persons in Error - PubMed (nih.gov)
Incorrect Administration of Adult RSV Vaccines to Young Children - PubMed
(nih.gov)5
Work group members (external)
ACIP Members
Sarah Long (chair)
Oliver Brooks
Camille Kotton
Denise JamiesonConsultants
Cody Meissner (Dartmouth Geisel School of Medicine)
Helen Chu (University of Washington)
Natasha Halasa (Vanderbilt University)
Daniel Feikin (World Health Organization)
Kevin Ault (Western Michigan University)
Pablo Sanchez (Nationwide Children’s Hospital)
Liaisons
James McAuley (IDSA)
Brenna L. Hughes (ACOG)
Nicole Chaisson (AAFP)
Sean O’Leary (AAP)
Jennifer Schuster (PIDS)
Molly Howell (AIM)
Dana DeShon (NAPNAP)GRADE/ EtRConsultants
Doug Campos -Outcalt
Rebecca MorganEx Officio Members
Lucia Lee (FDA -CBER)
Judy Beeler (FDA -CBER)
Yodit Belew (FDA -CDER)
Yugenia Hong -Nguyen (FDA -CDER)
Sonnie Kim (NIH -NIAID)
April Killikelly (Public Health Agency of Canada)
Winnie Siu (Public Health Agency of Canada)
Jessica Lee (CMS/CMCS)
T erry Dalle -T ezze (HRSA)
Matthew Clark (IHS)
6
Work group members (CDC)
Amber Winn
Chris Taylor
Tami Skoff
Angie Campbell
Michael Melgar
Amanda Payne
Noelle Molinari
Claire Midgley
Fiona Havers
Pragna Patel
Amadea BrittonRuth Link -Gelles
Megan Wallace
Monica Godfrey
Karen Broder
Naomi T epper
Heidi Moline
Hannah Rosenblum
Derrell Powers
Raigan Wheeler
Sally Ezra
Manisha PatelCDC ACIP Staff
Melinda Wharton
Stephanie Thomas
Jessica MacNeilDemorah Hayes
Elizabeth Greene
Monica Patton
Jarrett Gartin
Dennis Wang
Jordan Singleton
Trang Nguyen Wisard
Fatimah Dawood
John Su
Michael McNeilCDC
Katherine Fleming -Dutra (co -lead)
Jefferson Jones (co -lead)
Danielle Moulia
Meredith McMorrow
Mila Prill
Natalie Thornburg
Aron Hall
Ismael Ortega -Sanchez
Melissa Coughlin
Jamison Pike
Lauren RoperA. Patricia Wodi
Christine Olson
Anne Hause
Andrew Leidner
David Shay
Sarah Meyer
Kristen Folsom
Julianne Gee
Agustin Lopez
Lakshmi Panagiotakopoulos
7
•Implementation and uptake of nirsevimab and maternal RSV vaccine — Dr.
Shannon Stokley (CDC/NCIRD)
•Maternal RSV vaccine safety surveillance — Dr. Pedro Moro (CDC/NCEZID)
•Summary of effectiveness of nirsevimab in infants — Dr. Amanda Payne
(CDC/NCIRD)
•Work Group considerations — Dr. Jefferson Jones (CDC/NCIRD)Agenda
8
For more information, contact CDC
1-800-CDC-INFO (232 -4636)
TTY: 1 -888-232-6348 cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position
of the U.S. Centers for Disease Control and Prevention.
Thank you